EUVIMEDEUVIMED entdecken
Crossref

Chrysin and its nanoliposome ameliorated non-alcoholic steatohepatitis via inhibiting TLR4 signalling pathway

Hao Liu iD, Ningman Jiang, Ge Kuang, Xia Gong, Jun Hu, Jin Liu, Xinru Yin, Shengwang Wu, Jingyuan Wan

Journal of Pharmacy and Pharmacology · 01.08.2023 · 75 (8) · 1046-1057

DOI: 10.1093/jpp/rgad031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 01.08.2023. Verfasst von Hao Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Department of Pharmacology, Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Non-alcoholic steatohepatitis (NASH) is a chronic liver disease histologically characterized by liver steatosis, hepatocellular injury, inflammation and fibrosis, resulting in cirrhosis and hepatocellular carcinoma, but effective measures and obvious pathogenesis for NASH remain elusive. Chrysin (CH) has been reported to have anti-inflammatory effects but shows lower bioavailability.

Methods

In this study, a chrysin nanoliposome (CH-NL) was first prepared and characterized. Then, we used the methionine–choline-deficient (MCD) diet to induce a mouse model of NASH. Finally, the effects of CH and CH-NL on NASH were evaluated in the liver of NASH mice. Key findings The results showed that CH or CH-NL significantly reduced the accumulation of lipids in hepatocytes, alleviated liver injury, decreased the generation of radical oxygen species, and attenuated the accumulation of collagen fibre in the liver of NASH mice. In addition, CH and its nano-liposomes markedly inhibited the production of inflammatory cytokines and inflammatory cell infiltration in the liver of NASH mice. Further studies found that CH-NL and CH-NL downregulated the MCD diet-induced activation of Toll-like receptor 4 (TLR4) signalling pathway in the liver of mice.

Conclusions

CH and its nanoliposome alleviated MCD diet-induced NASH in mice, which might be through inhibiting TLR4 signalling pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseMiceAnimalsToll-Like Receptor 4LiverFlavonoidsDietMethionineCholineDisease Models, AnimalMice, Inbred C57BL

Stichwörter der Autor:innen

Toll-like receptor 4chrysinnanoliposomenon-alcoholic steatohepatitis

Substanzen

chrysinToll-Like Receptor 4FlavonoidsMethionineCholine

Autor:innen und Institutionen

  • Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Department of Pharmacology, Chongqing Medical University, Chongqing, China.
  • Department of Anatomy, Chongqing Medical University, Chongqing, China.
  • Department of Gastroenterology, Institute of surgery Research, Daping Hospital, Army Medical University, Chongqing, China.
  • Department of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, China.

ORCID-Profile: Hao Liu

Förderung

  • Natural Science Foundation of China

Zitieren

APA

Liu, H., Jiang, N., Kuang, G., Gong, X., Hu, J., Liu, J., Yin, X., Wu, S., & Wan, J. (2023). Chrysin and its nanoliposome ameliorated non-alcoholic steatohepatitis via inhibiting TLR4 signalling pathway. Journal of Pharmacy and Pharmacology, 75(8), 1046-1057. https://doi.org/10.1093/jpp/rgad031

Vancouver

Liu H, Jiang N, Kuang G, Gong X, Hu J, Liu J, et al. Chrysin and its nanoliposome ameliorated non-alcoholic steatohepatitis via inhibiting TLR4 signalling pathway. Journal of Pharmacy and Pharmacology. 2023;75(8):1046-1057. doi:10.1093/jpp/rgad031

BibTeX
@article{Liu2023,
  author = {Liu, Hao and Jiang, Ningman and Kuang, Ge and Gong, Xia and Hu, Jun and Liu, Jin and Yin, Xinru and Wu, Shengwang and Wan, Jingyuan},
  title = {Chrysin and its nanoliposome ameliorated non-alcoholic steatohepatitis via inhibiting TLR4 signalling pathway},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2023},
  volume = {75},
  number = {8},
  pages = {1046--1057},
  doi = {10.1093/jpp/rgad031}
}
Kostenlos starten →